Cristina R Reschke Selected Research

Antagomirs

11/2021	Antagomir-mediated suppression of microRNA-134 reduces kainic acid-induced seizures in immature mice.
1/2021	Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy.
1/2019	Antagonizing Increased miR-135a Levels at the Chronic Stage of Experimental TLE Reduces Spontaneous Recurrent Seizures.
1/2018	Spared CA1 pyramidal neuron function and hippocampal performance following antisense knockdown of microRNA-134.
3/2017	Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy.
7/2015	Antagomirs targeting microRNA-134 increase hippocampal pyramidal neuron spine volume in vivo and protect against pilocarpine-induced status epilepticus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cristina R Reschke Research Topics

Disease

13	Seizures (Absence Seizure) 01/2022 - 01/2015
12	Epilepsy (Aura) 01/2022 - 01/2015
8	Status Epilepticus (Complex Partial Status Epilepticus) 11/2021 - 07/2015
3	Temporal Lobe Epilepsy 10/2020 - 01/2019
2	Schizophrenia (Dementia Praecox) 03/2022 - 01/2022
2	Neuroinflammatory Diseases 01/2022 - 01/2021
2	Inflammation (Inflammations) 01/2020 - 01/2015
1	Memory Disorders (Memory Loss) 03/2022
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022
1	Myoclonic Epilepsies (Myoclonic Encephalopathy) 10/2021
1	Gliosis 01/2020
1	Hypoxia (Hypoxemia) 01/2017
1	Brain Injuries (Brain Injury) 12/2015
1	Nervous System Diseases (Neurological Disorders) 07/2015

Drug/Important Bio-Agent (IBA)

7	MicroRNAs (MicroRNA)IBA 10/2020 - 01/2015
6	Kainic Acid (Kainate)IBA 01/2022 - 07/2015
6	AntagomirsIBA 11/2021 - 07/2015
4	Antisense OligonucleotidesIBA 11/2021 - 07/2019
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2017
3	OligonucleotidesIBA 01/2021 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 10/2020 - 01/2015
2	Pharmaceutical PreparationsIBA 03/2022 - 01/2020
2	Pilocarpine (Ocusert)FDA LinkGeneric 10/2021 - 07/2015
2	Pentylenetetrazole (Metrazol)IBA 01/2018 - 03/2017
2	Anticonvulsants (Antiepileptic Drugs)IBA 03/2017 - 07/2015
2	Adenosine Triphosphate (ATP)IBA 01/2017 - 12/2015
2	Purinergic P2X7 ReceptorsIBA 01/2017 - 12/2015
1	Ketamine FDA LinkGeneric 03/2022
1	Glutamic Acid (Glutamate)FDA Link 03/2022
1	Dizocilpine Maleate (Dizocilpine)IBA 03/2022
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 03/2022
1	Claudin-5IBA 01/2022
1	RepSoxIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2021
1	Neuroprotective AgentsIBA 01/2021
1	Taurine FDA Link 01/2021
1	Amino Acids FDA Link 01/2021
1	Circulating MicroRNAIBA 10/2020
1	CholesterolIBA 03/2017
1	locked nucleic acidIBA 03/2017
1	Phenobarbital (Luminal)FDA Link 01/2017
1	3- (5- (2,3- dichlorophenyl)- 1H- tetrazol- 1- yl)methylpyridineIBA 01/2017
1	Neurotransmitter Agents (Neurotransmitter)IBA 12/2015
1	CytokinesIBA 12/2015
1	Cholinergic AgonistsIBA 07/2015
1	Ion Channels (Ion Channel)IBA 01/2015

Therapy/Procedure

3	Therapeutics 01/2021 - 01/2015
1	Induced Hyperthermia (Thermotherapy) 01/2022
1	Investigational Therapies (Experimental Therapy) 10/2021
1	Intraperitoneal Injections 01/2021
1	Injections 03/2017